- US-listed companies
- Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.DCPH
Market cap
$2.1B
P/E ratio
Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
Total revenues | - | - | 25 | 42 | 96 | 134 | 163 |
Cost of sales | - | - | - | 0 | 3 | 9 | 4 |
Research and development | 40 | 83 | 158 | 199 | 257 | 188 | 234 |
Selling, general, and administrative | - | - | - | 114 | 136 | 120 | 136 |
Total cost and operating expenses | - | - | - | 313 | 396 | 317 | 374 |
Loss from operations | -51 | -104 | -201 | -271 | -300 | -183 | -211 |
Interest and other income, net | 1 | 4 | 9 | 5 | 0 | 5 | 16 |
Total other income (expense), net | 1 | 4 | 8 | 5 | 0 | 5 | 16 |
Loss before income tax expense | - | - | - | - | - | -178 | -195 |
Current Income Tax Expense (Benefit) | - | - | - | - | - | 1 | 0 |
Income tax expense | - | - | - | - | - | - | 0 |
Net loss | -50 | -100 | -192 | -266 | -300 | -179 | -195 |
Earnings Per Share, Diluted | - | - | - | - | - | -2.37 | -2.29 |
Earnings Per Share, Basic | - | - | - | - | - | -2.37 | -2.29 |
Earnings Per Share, Basic | - | - | - | - | - | -2.37 | -2.29 |
Earnings Per Share, Diluted | - | - | - | - | - | -2.37 | -2.29 |
Net loss | -50 | -100 | -192 | -266 | -300 | -179 | -195 |
Unrealized gains (losses) on marketable securities | - | - | 0 | -0 | -0 | -1 | 1 |
Currency translation adjustment | - | - | - | - | 0 | -0 | 1 |
Total other comprehensive income (loss) | - | - | 0 | -0 | 0 | -1 | 2 |
Total comprehensive loss | - | - | -192 | -267 | -300 | -180 | -193 |